Cite
HARVARD Citation
Isoyama, S. et al. (2021). Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. Journal for immunotherapy of cancer. 9 (8), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Isoyama, S. et al. (2021). Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. Journal for immunotherapy of cancer. 9 (8), p. . [Online].